Tag: Cancer: Misc.
Delays in Cancer Surgery Due to COVID-19 Could Harm Survival
Per-patient delay of three or six months would result in an estimated 92,214 or 208,275 life-years lost
11.2 Percent of Pediatric Cancer Patients Positive for SARS-CoV-2
Rate of positivity 29.3 percent among screen- or symptom-positive patients; 2.5 percent in asymptomatic patients
Opioid-Related Deaths Less Likely Among Cancer Patients
Mortality lower despite common opioid prescriptions for cancer-related pain
COVID-19 Pandemic Slowing Cancer Research
Findings based on survey of American Cancer Society research grantees
PM2.5 Linked to Later Mortality in Certain Pediatric, AYA Cancers
Mortality risk increased at 5 years, 10 years among those with pediatric lymphomas, CNS tumors
IBD Not Tied to Female Genital Tract Malignancies
Findings seen in a national sample of Dutch patients from 1991 to 2015
UGN-101 Active in Chemoablation of Upper Tract Urothelial Cancer
Fifty-nine percent of patients had complete response at four to six weeks after initial therapy
Health Insurance Coverage Disruption Impedes Cancer Care
Findings consistent across cancer continuum, from screening to treatment and end-of-life care
Fewer Children Enrolling in Pediatric Cancer Trials
Adolescent and young adult cancer patients underrepresented in clinical trials
Patients With Cancer Seem More Vulnerable to COVID-19
Frequency of severe events highest for patients with hematologic cancer, lung cancer, and metastatic cancer
